Latest / Morning Medical with Dr. Chow / Dolly Parton's Healthcare Legacy, Paxlovid for Long COVID, and Back-to-School Vaccinations

Transcript

Dolly Parton's Healthcare Legacy, Paxlovid for Long COVID, and Back-to-School Vaccinations · Morning Medical with Dr. Chow

• 0:00
  Welcome back to another episode of Morning Medical with Dr.
• 0:02
  Chow, where we bring you the latest updates in the medical and health world.
• 0:07
  I'm your host, Dr.
• 0:08
  Chi-Ming Chow, and today, we're going to explore an intriguing perspective on why the
• 0:13
  legendary Dolly Parton serves as an excellent role model for doctors.
• 0:20
  Dolly Parton, who recently passed away at the age of eighty, left behind not only a
• 0:24
  remarkable legacy in music and entertainment but also a profound impact on humanitarian and
• 0:30
  healthcare initiatives.
• 0:32
  Many qualities that made Parton successful are exactly what the medical field needs today.
• 0:38
  Let's delve into how Parton's life and work can inspire us as healthcare professionals.
• 0:44
  First and foremost, Parton was humble while achieving extraordinary success.
• 0:49
  Despite her fame and accomplishments, she remained down-to-earth and approachable.
• 0:54
  In medicine, patients often place us on a pedestal because of our knowledge and stature.
• 1:00
  However, it's crucial to emulate Parton's humility and avoid becoming unapproachable.
• 1:07
  Compassion and empathy should always be at the core of our interactions with patients.
• 1:13
  Parton never forgot her roots, growing up in a two-room cabin in the Appalachian woods with no
• 1:18
  running water or electricity.
• 1:20
  Her early life challenges fueled her drive to excel.
• 1:24
  Similarly, as doctors, we should always remember the years of training and the
• 1:28
  challenges we faced.
• 1:30
  Medicine is ultimately about the patients, not just our credentials or status.
• 1:36
  Another admirable quality of Parton was her generosity.
• 1:40
  She used her success to help others, notably through initiatives like the Imagination
• 1:44
  Library, which has donated over 330 million books to children.
• 1:49
  Physicians have a similar opportunity to give back by mentoring, teaching, volunteering, and
• 1:54
  serving our communities.
• 1:56
  Our respected position in society comes with the responsibility to contribute positively.
• 2:01
  Parton also had a unique ability to make people feel seen and valued.
• 2:07
  She understood the importance of how people feel, and this is something we can incorporate
• 2:12
  into our practice as well.
• 2:14
  A warm smile, humor, and genuine interest can be therapeutic, even if they don't change the
• 2:21
  diagnosis.
• 2:22
  A simple touch or consoling words can have a significant impact on our patients.
• 2:28
  Moreover, Parton wasn't afraid to reinvent herself.
• 2:32
  She continuously evolved, whether as a musician, actor, or philanthropist.
• 2:37
  In a rapidly changing medical landscape, with artificial intelligence and new technologies,
• 2:41
  we must embrace change and be willing to adapt.
• 2:46
  Parton's life reminds us that our identities can expand beyond just being a doctor.
• 2:52
  Parton was also consistent in protecting her personal brand.
• 2:56
  She knew what she stood for, and this consistency is something we can learn from.
• 3:02
  As doctors, we should consider what we want our patients and colleagues to remember about us.
• 3:09
  Parton faced adversity throughout her life, from poverty to criticism and stereotypes, yet
• 3:14
  she turned these challenges into motivation.
• 3:18
  In healthcare, we often face similar adversities, including malpractice suits.
• 3:23
  It's important to use these challenges as learning experiences and not let them define
• 3:27
  us.
• 3:29
  Humor was one of Parton's superpowers, and she never took herself too seriously.
• 3:35
  Medicine is a serious field, but appropriate humor can make us more approachable and help
• 3:40
  build cohesive teams.
• 3:42
  Levity can have its place in healthcare when used appropriately.
• 3:48
  Finally, Parton's authenticity shone through in everything she did.
• 3:53
  She was unapologetically herself, and that's a crucial lesson for us as physicians.
• 3:58
  While it's important to follow protocols and guidelines, we mustn't lose sight of being
• 4:03
  genuine and letting our personalities shine through.
• 4:08
  Patients want to know there's a human being behind the white coat, and authenticity builds
• 4:13
  trust, which is the foundation of the physician-patient relationship.
• 4:18
  In conclusion, while Dolly Parton might seem like an unlikely role model for doctors, her
• 4:22
  career, built on humility, authenticity, resilience, generosity, and adaptability,
• 4:28
  offers valuable lessons for us.
• 4:30
  Perhaps her greatest lesson for doctors is to take our work seriously but never become too
• 4:35
  important to be kind.
• 4:38
  Today, we're examining a recent study that looked into the effectiveness of Paxlovid, or
• 4:44
  nirmatrelvir-ritonavir, for treating long COVID.
• 4:48
  The study, which was a large double-blind phase II trial called RECOVER-VITAL, was sponsored by
• 4:54
  the National Institutes of Health.
• 4:57
  It aimed to determine whether Paxlovid could alleviate symptoms of long COVID, a condition
• 5:03
  that affects more than five percent of adults in the United States and is characterized by
• 5:08
  symptoms such as cognitive dysfunction, autonomic dysfunction, and exercise
• 5:13
  intolerance.
• 5:15
  The trial included 959 adult participants from 69 sites across the United States, who had a
• 5:22
  suspected, probable, or confirmed case of COVID-19 and were experiencing moderate to
• 5:28
  severe symptoms of long COVID.
• 5:31
  Participants were randomly assigned to one of three treatment regimens: a 15-day course of
• 5:38
  nirmatrelvir-ritonavir, a 25-day course, or a placebo regimen paired with ritonavir to
• 5:45
  maintain blinding due to its distinctive taste.
• 5:49
  Despite initial hopes, the results showed that Paxlovid did not significantly differ from the
• 5:55
  placebo in reducing symptoms of long COVID across the three symptom phenotypes.
• 6:01
  The study found that improvement rates in cognitive dysfunction, autonomic dysfunction,
• 6:06
  and exercise intolerance were similar between the groups receiving the antiviral and those on
• 6:11
  placebo.
• 6:13
  For example, improvement in cognitive symptoms was seen in 53 to 58 percent of those on
• 6:19
  Paxlovid, compared to 55 percent on placebo, showing no meaningful difference.
• 6:25
  One of the main hypotheses for the trial was that viral persistence might be driving long
• 6:30
  COVID symptoms, and treating it with an antiviral like Paxlovid could help.
• 6:35
  However, the results did not support this hypothesis.
• 6:39
  The researchers noted that optimal endpoint timing for assessing long COVID treatment is
• 6:44
  still unclear, and the trial did not specifically enroll patients with evidence of
• 6:49
  viral persistence, who might benefit most from antiviral treatment.
• 6:53
  Interestingly, the trial also highlighted the importance of placebo controls in long COVID
• 6:59
  studies.
• 7:00
  The improvement observed in placebo recipients underscores the potential for psychological and
• 7:05
  other non-specific effects in symptom management.
• 7:08
  This suggests that, while antiviral treatment might not show a direct benefit, the placebo
• 7:14
  effect itself can be quite powerful in managing long COVID symptoms.
• 7:19
  Despite the lack of significant findings, the study did provide useful insights.
• 7:24
  It confirmed that extending the course of nirmatrelvir-ritonavir to 25 days was generally
• 7:29
  safe, with only mild transient side effects like nausea and diarrhea reported more
• 7:35
  frequently than with ritonavir alone.
• 7:39
  However, the study also pointed out several limitations, including the lack of consistent
• 7:44
  definitions for long COVID diagnosis and validated assessment tools for symptoms, which
• 7:49
  could have influenced the results.
• 7:52
  In summary, while the RECOVER-VITAL trial did not find Paxlovid to be more effective than
• 7:58
  placebo for treating long COVID symptoms, it highlights the complexity of this condition and
• 8:04
  the challenges in addressing it.
• 8:07
  As research continues, it's crucial to refine our understanding of long COVID and develop
• 8:14
  more targeted treatment strategies.
• 8:17
  Until then, the findings remind us of the importance of using rigorous scientific
• 8:21
  methods, including placebo controls, to truly understand what works and what doesn't in the
• 8:27
  treatment of complex conditions like long COVID.
• 8:32
  With the new school year just around the corner, public health officials are sounding
• 8:35
  the alarm about the importance of getting vaccinated against preventable diseases.
• 8:40
  In Canada, as millions of children prepare to return to school, there is a heightened focus
• 8:45
  on vaccines for illnesses such as COVID-19, respiratory syncytial virus, influenza, and
• 8:52
  measles.
• 8:54
  The push for vaccinations comes amid concerns of a resurgence in these illnesses,
• 8:59
  particularly as children gather in close quarters in schools.
• 9:03
  Health officials emphasize that vaccines are a crucial line of defense, not only protecting
• 9:08
  the individuals who receive them but also helping to safeguard communities by reducing
• 9:13
  the spread of these diseases.
• 9:16
  Recent reports have highlighted the risks associated with vaccine-preventable diseases,
• 9:21
  especially measles, which poses a significant threat if it takes hold in a community.
• 9:27
  Measles is highly contagious and can lead to severe health complications.
• 9:32
  The potential for outbreaks is particularly worrying in areas with lower vaccination rates,
• 9:37
  underscoring the need for widespread immunization.
• 9:41
  In some regions, like York, Ontario, public health agencies have already issued warnings
• 9:45
  about possible measles exposure.
• 9:48
  While there are currently no active measles cases in British Columbia, health officials are
• 9:53
  on high alert for new virus strains that could emerge as the school year begins.
• 9:58
  The urgency of these warnings is compounded by the fact that, in recent years, there has been
• 10:04
  a decline in routine vaccination rates.
• 10:07
  This decline can be attributed to a variety of factors, including pandemic-related disruptions
• 10:12
  to healthcare services and vaccine hesitancy fueled by misinformation.
• 10:18
  Health authorities are urging parents to ensure their children are up to date with their
• 10:22
  vaccinations.
• 10:23
  They are also encouraging adults to review their vaccination status and get any necessary
• 10:28
  booster shots.
• 10:30
  The aim is to prevent the healthcare system from becoming overwhelmed, especially during
• 10:34
  the fall and winter months when respiratory infections are more prevalent.
• 10:40
  Overall, the message from public health officials is clear: vaccines are a safe and
• 10:44
  effective way to protect against serious diseases.
• 10:47
  As the school year kicks off, it's more important than ever to heed this advice and
• 10:51
  take proactive steps to protect ourselves and our communities.
• 10:57
  In our final segment today, we're diving into a recent study that raises concerns about the
• 11:02
  potential dangers of driving after consuming cannabis edibles.
• 11:07
  Published in the Journal of the American Medical Association Network Open, the study
• 11:12
  highlights the challenges faced by law enforcement in identifying impaired drivers
• 11:16
  when standard blood tests may not tell the whole story.
• 11:21
  While most previous research on cannabis and driving has focused on smoked or inhaled
• 11:25
  marijuana, which quickly elevates tetrahydrocannabinol levels in the bloodstream,
• 11:31
  this study zeroes in on edibles.
• 11:34
  Edibles are absorbed more slowly through the digestive system.
• 11:38
  As a result, they can impair driving even when blood tetrahydrocannabinol levels are below
• 11:44
  legal limits.
• 11:46
  The study was conducted by researchers at the Centre for Addiction and Mental Health in
• 11:50
  Toronto, where they tested 40 healthy adult volunteers who regularly use cannabis.
• 11:56
  Participants consumed soft-chew gummies containing varying doses of
• 12:00
  tetrahydrocannabinol: 0, 2, 10, or 20 milligrams.
• 12:06
  Their driving skills were then assessed using a simulator at two, five, and 24 hours after
• 12:12
  consumption.
• 12:14
  Results showed that the 10- and 20-milligram doses led to significant driving impairments.
• 12:20
  Participants had trouble maintaining lane position, showed slower reaction times, and
• 12:27
  experienced greater speed fluctuations compared to those who took the placebo.
• 12:33
  Interestingly, despite these impairments, blood tests showed tetrahydrocannabinol levels below
• 12:40
  the 5 nanograms per milliliter threshold commonly used to determine impairment.
• 12:47
  Participants themselves reported feeling less confident in their driving abilities and were
• 12:52
  more hesitant to drive after consuming the gummies.
• 12:55
  This self-awareness, while beneficial, underscores the subjective nature of impairment
• 13:01
  that blood tests alone might not capture, especially with edibles.
• 13:06
  This study points to a complex challenge for policymakers and law enforcement.
• 13:10
  The slow absorption and prolonged effects of edibles, unlike smoked cannabis, complicate the
• 13:16
  interpretation of biological measures.
• 13:18
  As Dr.
• 13:19
  José Ignacio Nazif-Munoz commented, there's a need for more reliable roadside tools to detect
• 13:24
  impairment from edibles.
• 13:27
  While the study provides valuable insights, it also has limitations.
• 13:31
  It was conducted using driving simulators rather than on actual roads, and it focused on
• 13:37
  regular cannabis users.
• 13:38
  The effects on occasional users might differ, and further research is needed to explore those
• 13:43
  differences.
• 13:45
  As we wrap up today's episode, it's clear that the landscape of impaired driving is evolving
• 13:50
  with the increased use of cannabis edibles.
• 13:53
  This research serves as a reminder of the importance of informed and cautious
• 13:57
  decision-making when it comes to driving after consuming any form of cannabis.
• 14:03
  Thank you for joining me on this episode of Morning Medical with Dr.
• 14:06
  Chow.
• 14:07
  Stay informed, stay healthy, and until next time, take care.